z-logo
open-access-imgOpen Access
Age at Renal Replacement Therapy in Autosomal Dominant Polycystic Kidney Disease
Author(s) -
Ana Gonzalo,
Araceli Gallego,
A Tato,
Joaquin Ortu ntilde o
Publication year - 1996
Publication title -
nephron
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.951
H-Index - 72
eISSN - 1423-0186
pISSN - 0028-2766
DOI - 10.1159/000189464
Subject(s) - medicine , renal replacement therapy , autosomal dominant polycystic kidney disease , polycystic kidney disease , polycystic kidney , kidney disease , nephrology , kidney , disease , urology
Ana Gonzalo, MD, Servicio de Nefrologia, Hospital Ramon y Cajal, Carretera de Colmenar Km 9,100, E-28034 Madrid (Spain) Dear Sir, In 1989 Gretz et al. [1] pointed out that end-stage renal failure appears earlier in men than in women in autosomal dominant polycystic kidney disease (ADPKD; median age 52 vs. 58 years). Data from the Australia and New Zealand Dialysis and Transplant Registry [2] and recently those from Gabow and Johnson [3] in ADPKDl patients supported Table 1. Age and sex distribution at the start of renal replacement therapy in 82 ADPKD patients

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom